Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Liao JB, Gwin WR, Urban RR, Hitchcock-Bernhardt KM, Coveler AL, Higgins DM, Childs JS, Shakalia HN, Swensen RE, Stanton SE, Tinker AV, Wahl TA, Ancheta RG, McGonigle KF, Dai JY, Disis ML, Goff BA.
Liao JB, et al. Among authors: disis ml.
J Immunother Cancer. 2021 Sep;9(9):e003122. doi: 10.1136/jitc-2021-003122.
J Immunother Cancer. 2021.
PMID: 34531249
Free PMC article.